Beta Bionics said this week that it won FDA approval to start recruiting patients with Type I diabetes for home-use studies of its iLet bionic pancreas system.
The trial is slated to test Novo Nordisk’s fast-acting insulin, Fiasp, with the company’s autonomous infusion pump in adults with Type I diabetes. The study will also evaluate insulin lispro and conventional insulin aspart combined with the iLet system in adults and kids with Type I diabetes, according to Beta Bionics.
Get the full story at our sister site, Drug Delivery Business News.
The post Beta Bionics wins FDA nod for home-use trial of artificial pancreas tech appeared first on MassDevice.
from MassDevice https://ift.tt/2LoFB4L
Cap comentari:
Publica un comentari a l'entrada